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ABSTRACT
Breast cancer treatment response varies by subtype, treatment regiment, and additionally by
vasculature characteristics. For this reason, breast cancer is a model disease for the
development of both targeted therapy and prognostic and predictive biomarkers.
Mathematical modeling allows for personalized patient specific prediction of treatment
outcome based on parameters found to be important to the cancer type. Mathematical
modeling is beneficial in providing insight into why cancer treatment fails and in what cases,
additionally determining what characteristics result in a successful treatment. Presented in
Chapter 1 is a scientific introduction and discussion focusing on representative modeling
works specified towards breast cancer which give quantitative insight into chemotherapy
resistance and how drug resistance can be overcome or minimized to optimize chemotherapy
treatment. Demonstrated in Chapter 2, a modeling tool was created to predict the likelihood
of response to neoadjuvant chemotherapy using patient specific tumor vasculature biomarkers
measured in a total of 48 patients. To perform accurate and rapid throughput, a semiautomated analysis was implemented, improving on previous methods requiring hand-made
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measurements. In effort to translate this model towards clinical practice, 48 patients
undergoing neoadjuvant chemotherapy were evaluated, collecting clinically relevant data
including pre- and post-treatment pathology specimens, and dynamic contrast-enhanced
magnetic resonance imaging. Analysis of histology parameters, specifically radius of drug source
divided by diffusion penetration distance (L/rb), a normalization penetration distance, and
blood volume fraction (BVF), provides a separation of patients obtaining a pathologic complete
response (pCR) and those that do not, with 80% accuracy (p= 0.0269), providing a personalized
approach to breast cancer treatment. Nanoparticles are shown to improve on cancer treatment
efficacy, demonstrating improved cell kill when compared to free drug. Due to drug resistance
and patient heterogeneity, patient outcome can vary greatly, in order to explore this
phenomenon mouse treatment outcome relative to tumor and organ nanoparticle deposition is
analyzed. A mouse study is presented in Chapter 3 as a proof-of-concept demonstrating the
heterogeneous distribution of nanoparticles, and the improved cancer cell kill efficacy in an
exponential fashion relative to accumulation of nanoparticles in the tumor. The combination of
using nanoparticles as improved drug delivery vehicles, analysis of tumor biomarkers, and
mathematical modeling to understand the underlying phenomena of treatment efficacy can be
used in the clinical setting to help improve cancer treatment, and identify patients likely to
respond well to differing and improved cancer treatment. Lastly, future directions are discussed
in Chapter 4 whereby the application of chemotherapy, nanotherapeutics, and mathematical
modeling may greatly improve and connect the theoretical and clinical side of cancer science.
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CHAPTER 1
INTRODUCTION

This chapter was adapted from:
Brocato, T.*; Dogra, P.*; Koay, E. J.; Day, A.; Chuang, Y.; Wang, Z.; Cristini, V. Understanding
Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports,
2014. 6(2): p. 110-120. (*Authors contributed equally to this work)
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1.1 Overview
Breast cancer continues to be a major cause of death in women in the United States and
globally.1 The lethality of this disease is related to its robust ability to resist anticancer
therapies.2 Drug resistance, either acquired or intrinsic, is believed to cause 90% of all
chemotherapy failures, and the 5- year survival rate for metastatic breast cancer in United State
is only 26%.3, 4 Multiple biological factors are believed to cause drug resistance, including
genetic alteration, bypass mechanisms, altered effectors in DNA repair, pathway independent
acquired resistance, pH alterations, and upregulation of efflux pumps in cellular membranes. 4-6
Another very important, but less-discussed reason that operates at a higher scale of
organization is the existence of physical barriers that limit diffusive and convective drug
transport in the required lethal drug concentrations to the regions of interest. The presence of
dense extracellular matrix and interstitial hypertension in the tumor microenvironment and
hostile conditions, marked by hypoxia and hyperacidity, affect drug penetration and drug
efficacy, respectively7-9, increasing tumor drug resistance when delivered in non-lethal
concentrations to the tumor.
Mathematical modeling has been widely used as a method complementary to
experimental investigations to provide insight into cancer initiation, progression, and invasion
in the past several decades.10, 11 Its importance is increasingly recognized for its capability to
interpret and integrate the massive amount of data that experimental biologists are currently
producing, especially in the era of data-intensive cancer research.12 Modeling approaches can
be briefly divided into 3 categories: discrete, continuum, and hybrid, ie, the combination of
both (the reader can refer to11, 13-17 for recent excellent reviews). Discrete models explicitly
2

represent individual cells (or part of a cell or a cluster of cells) in space and time, and then track
and update their states and interactions according to predefined computational rules derived
from experimental data. In contrast, continuum models represent the tumor as a continuous
mass rather than as discrete components, and give information about the overall tumor
morphologic behavior while neglecting the influences of individual cells. By drawing on the
strengths of both continuum and discrete descriptions, hybrid modeling provides a more
complete description of the tumor and its microenvironment, hence, having been accepted as
the more desirable choice. Regardless of the modeling technique used, computational
oncologists should note that the development of a successful cancer model is a long-term,
integrative, and iterative process, where available experimental data are used to guide the
model design and to validate the model.
Significant progress has been made in mathematical modeling of cancer drug resistance
to understand how biological and physical factors of the tumor influence therapeutic outcomes.
Mathematical models have applications that range from describing drug delivery, predicting cell
kill from cytotoxic therapies, and anticipating tumor growth, among many others.14 The ability
to predict tumor-related outcomes aids the interpretation of experimental data and generation
of specific biological/medical hypotheses. In this review, we will discuss the progress that has
been made in mathematically describing fundamental processes in signaling networks and the
tumor microenvironment, highlighting how the physical sciences can contribute to our
understanding and treatment of breast cancer and other tumors.

3

1.2 Molecular Level Modeling
Overexpression of Efflux Pumps
Molecular level alterations and mutations can promote tumor formation and cellular
drug resistance13, which can cause hypersensitivity and overexpression of receptors, promoting
tumor cell proliferation. For example, P-glycoprotein overexpression effectively lowers the
intracellular concentration of chemotherapy, enabling cellular resistance to toxic drugs. Atari et
al18 studied drug resistance mechanisms of topotecan in breast cancer based on efflux pumps
and drug resistance proteins. The primary efflux pump modeled, breast cancer resistance
protein (BCRP), is known to be expressed in high concentrations in membranes of resistant
tumor cells. A quasi-steady nonlinear drug kinetic model was developed in this study with
consideration of a single cell’s compartments, comprising the matrix, extracellular region, cell
membrane, cytoplasm, and nucleus. This model demonstrates that topotecan resistance can be
predicted from BCRP expression in the various compartments, which could aid the design of
optimal dosing regimens.
P-glycoprotein Transfer between Cells
Cell-to-cell transfer of P-glycoprotein from resistant cells to sensitive cells not currently
expressing P-glycoprotein is observed in cancer drug resistance.19 Pasquier et al studied the role
of P-glycoprotein expression in MCF-7 breast cancer cells using a time-dependent mathematical
model based on a continuum population density function.3 The model investigated and
quantified how the overall drug resistance was affected by rates of cell proliferation and death,
4

P-glycoprotein induction and degradation, and P-glycoprotein transfer between cells. Their
simulation results showed that the transfer of P-glycoprotein between breast cancer cells
confers the multidrug resistance phenotype to cells not expressing P-glycoprotein.
HER2 Induced Drug Resistance
Breast cancer drug resistance of HER2 (human epidermal growth factor receptor; also
known as ErbB2) targeting agents, including monoclonal antibodies for HER2-positive breast
cancer, pertuzumab and trastuzumab, and/or a tyrosine kinase inhibitor, lapatinib, have been
well studied.20-22 Overexpression of HER2, found in 20%–30% of breast cancers23, has a negative
prognosis for survival.24 Faratian et al used a systems biology approach to formulate a kinetic
model that is predictive of resistance in response to receptor tyrosine kinase inhibitors. They
found that the expression level of PTEN (a tumor suppressor protein) is the only significant
predictor of survival by treatment with trastuzumab.20 Kirouac et al used a multiscale network
based pharmacokinetic and Pharmacodynamics model to determine the best combination
treatment for HER2-amplified breast cancer cells, which resulted in the combination of
trastuzumab, lapatinib, and an ErbB3 inhibitor, MM-111 being the most effective of the
combinations tested.21 Application of this model in a clinical setting will determine the best
mixture of various chemotherapy drugs tominimize resistance in HER2-positive breast cancer.
Niepel et al developed a mathematical model based on partial least-squares regression method
to determine ligands that predict the response to treatment. Heregulin and ErbB3 were found
to be good predictors of drug response. Clinically, this model can be used to determine
biomarkers of drug sensitivity and resistance.22 Vera et al also created a kinetic model, which
determined chemoresistance based on genetic signatures of transcription factors E2F1 (positive
5

regulation of proapoptotic genes) and miR-205 (repression of antiapoptotic genes).25 Results of
this model demonstrate that genetic signatures can predict chemoresistance, helping to stratify
patients for risk of therapy failure.
The Effect of the Cell Cycle on Chemotherapy
The cell cycle was found to play an important role in expression of P-glycoprotein and
drug resistance. Roe-Dale et al26 determined that breast cancer patients given sequential drug
treatment of doxorubicin (DOX) followed by CMF (cyclophosphamide, methotrexate, and 5fluoruracil) was more successful in reducing drug resistance than patients given alternating
amounts of CMF and DOX in cycles. Chemotherapy drugs are found to be toxic in a cell-stage
dependent manner, with DOX being more effective in the beginning and late portions of the cell
cycle, and the CMF drugs being most effective in the beginning of the cell cycle. Specifically in,26
modeling of the cell cycle and its effect on multidrug resistance through the use of successful
sequential drug treatment compares 4 ordinary differential equation models (for drug
treatment, cell cycle, drug resistance, and a combination of cell cycle and drug resistance,
respectively), to determine importance of cell cycle and resistance on cell kill. The cell cycle and
resistance model accounted for (1) cell cycle stage based on amount of DNA in a cell in a given
stage and (2) cell cycle and accumulation of drug sensitivity due to P-glycoprotein. Their
simulation results were consistent with patient and experimental data, with cellular drug
resistance having a bigger impact than cell cycle stage.

1.3 Tissue-Scale Modeling
6

Overview: Biophysical Barriers to Drug Delivery and Therapeutic Resistance
Solid tumors (including breast cancer) are either drug resistant at initiation of
chemotherapy, or become resistant with the progression of therapy, arguably because of
selection pressure induced by cytotoxic agents on surviving cells.27 As discussed in the previous
section, the molecular principles of drug resistance play an important role in making cancerous
cells refractory to treatment. Before these molecular/cellular mechanisms come into picture, 2
very critical aspects contribute to therapeutic resistance: drug delivery across the tumor and
physiology of the tumor microenvironment.9 The tumor microenvironment can be divided into
3 components: (1) cancer cells, (2) interstitium, which consists of stromal cells (fibroblasts and
inflammatory cells) and the extracellular matrix (ECM), and (3) tumor microvasculature.28 This
environment is hostile to normal cells and is characterized by hypoxia, hypoglycemia, ATP
depletion, acidosis, denser than normal ECM, and elevated interstitial fluid pressure (IFP)
compared with normal tissue.9, 29 This biochemical environment affects cellular behavior and
drug chemistry, enabling tumor cells to survive chemotherapy. The microenvironment also
poses a direct barrier to drug delivery. After a drug reaches the tumor microvasculature,
extravasation from the microvasculature is the first challenge to overcome to enter the tumor
interstitium.30 Subsequently, drug molecules must penetrate through the abnormal tumor
interstitium, cross the individual cancer cell membranes and eventually reach their subcellular
targets. The transit from within the microvasculature to the inside of a cell is accompanied by
biophysical and biochemical barriers of the microenvironment, and molecular barriers of cancer
cells. Thus, the tumor microenvironment confers drug resistance in 2 ways, biochemical
gradients and biophysical barriers [7–9, 27].7-9, 27
7

As a tumor grows in its vascular growth phase in a confined volume, it faces 2 kinds of
solid stress: external stress and residual stress, applied by surrounding normal tissue and by the
growing tumor, respectively. This stress is of the order of 1.3–13.0 kPa, sufficient enough for
causing the collapse of blood and lymph microvessels. Vascular collapse of lymphatics leads to
poor extracellular fluid drainage, whereas collapse of blood microvessels has implications for
poor drug delivery and transport of oxygen, nutrients, etc.31, 32 As indicated previously, tumor
vasculature is drastically abnormal compared with healthy tissues. The “leaky” nature of tumor
vasculature has been exploited in the passive targeting of drugs,33 but a downside of this
leakiness is the development of interstitial hypertension. Because of vascular hyperpermeability
and poor lymphatic drainage, particularly at the center of the tumor, excess fluid accumulates
in the interstitium, elevating the IFP. IFP equilibrates with microvascular pressure, which
nullifies the pressure gradient required for extravasation of drug molecules on account of
convection with the outgoing fluid. Thus, elevated IFP is a formidable barrier to convective
transport, limiting the drug molecules from exiting the vascular compartment, 34, 35 and tends to
exert an isotropic fluid-phase stress that also has direct implications for vascular collapse.31, 36
Following extravasation, the penetration through tumor interstitium occurs primarily via
drug gradient-driven passive diffusion, and to some extent through convection. Usually, IFP
tends to diminish pressure gradients on account of its fairly uniform elevation across the tumor,
thus, diffusion remains the major determinant of interstitial migration of drug molecules. 35
However, diffusion of molecules through the interstitium to reach tumor cells at a distance
from blood vessels is met by immense physicochemical resistance, which tends to hamper drug
distribution.7, 8, 37 Diffusion barriers within the interstitium occur on account of factors, such as
8

cellular adhesion, dense packing of tumor cells, composition of ECM, solid and fluid stress, and
large distances between vessels.38 The physicochemical properties of drugs, such as size and
charge also affect their passage through the interstitium on account of their electrostatic,
hydrodynamic, and steric interactions with the ECM.39
Clinical Trials Assessing Drug Delivery and Transport
Several trials have analyzed drug delivery in patients to variable degrees of
sophistication to understand the factors that influenced how much drug reached the intended
target. For example, gemcitabine delivery was measured for patients with squamous cell
cancers of the head and neck,40 but factors related to delivery were not assessed in this trial.
The main goal of delivery measurement was to determine whether specific doses of
gemcitabine were sufficient for detectable delivery. The transport-related changes after antiangiogenic therapy have also been assessed, supporting the hypothesis of vascular
normalization.41 In a study conducted in breast cancer patients treated with doxorubicin, it was
seen that drug did not reach all parts of the tumor tissue, and gradients were established with
more drug in the periphery of the tumor than its center. This effect was more pronounced in
tumors with dense packing of cancer cells.42 The effects of paclitaxel and doxorubicin on
interstitial fluid pressure and oxygenation were measured in a trial of neoadjuvant
chemotherapy for patients with breast cancer, showing that paclitaxel improved the transport
properties of the tumors whereas doxorubicin did not. This provides rationale to optimize the
sequence of chemotherapies.41 In another study done on mouse models of various solid
tumors, similar trends of exponential decrease in doxorubicin concentration with increasing
distance from nearby blood vessels were observed.43 These studies demonstrate nonuniformity
9

of drug distribution across the tumor and indicate potential involvement of biophysical barriers
in thwarting chemotherapy.
We recently published a first-in-kind clinical trial of intraoperative gemcitabine infusion
for patients with resectable pancreatic cancer.44 The objectives were to measure the
incorporation of gemcitabine into the DNA of tumor cells and understand the factors that
influence delivery. We used semiquantitative scoring of the pathology to assess stromal score
and the staining levels of the cellular transporter of gemcitabine, hENT1,45 which may be
associated with outcome in pancreatic cancer. We also developed a mathematical model to
describe the changes in density during routine contrast-enhanced computed tomography (CT)
imaging of patients with pancreatic cancer. We discovered that gemcitabine delivery to the
cellular DNA could be described by multi-scale transport phenomena, as characterized by both
the stromal score and hENT1 levels. Furthermore, the CT-derived transport properties also
correlated with the drug delivery. We extended our CT transport analysis to 110 patients who
received protocol-based neoadjuvant gemcitabine-radiation for resectable pancreatic cancer,
and found that the pre-therapy CT-derived transport properties correlated with pathologic
response and survival. Thus, transport properties of pancreatic cancer describe the delivery of,
response to, and survival after gemcitabine-based therapies.
Extending these methods to patients with breast cancer would help to identify the
major biophysical barriers to drug delivery. Such efforts could aid the design of new therapeutic
strategies that overcome these physical impediments. If combined with mathematical oncology
approaches, these clinical trials could provide a mechanistic understanding of drug delivery for
each patient.
10

Vascular Supply of Drugs
A mathematical model by Sinek et al46 accounted for the morphologic and vascular
heterogeneity of tumors, and predicted the effectiveness of anticancer agents. The model
employed a multiscale tumor growth and angiogenesis simulator47 based on an adaptive finite
element mesh by Cristini et al48 for simulating tumor growth and response to chemotherapy
administration. Simulation results showed that tumor microenvironmental factors relevant to
drug, oxygen, and nutrient distribution led to variations in tumor response to chemotherapy,
implicating this variable drug delivery as a cause of therapeutic resistance. This model can
potentially serve as a tool for predicting in vivo pharmacokinetics of anticancer agents.
Baish et al49 developed a mathematical model using fluorescent vascular images to
determine the effect of architectural, physiological and branching irregularities of tumor
vasculature on the delivery of therapeutic agents and nutrients. By calculating δmax (maximum
distance from the nearest blood vessel) and λ (a measure of shape of voids between vessels)
from vascular images, the authors showed that the model predicted the amount of “material”
(eg, nutrients and therapeutic drugs) and the time required for the material to reach its
destination. The model predicted diffusion in irregularly shaped domains and evaluated the
efficacy of therapeutic agents that induce “vascular normalization”.50 This mathematical model
accounted for the existence of diffusion barriers pertinent to irregular vasculature and can be
used to quantify the effect of such impediments on drug delivery. Thurber et al51 also
developed a model using in vivo images of drug distribution around tumor vasculature from
murine tumor models. Their model predicted drug distribution profiles along the vasculature
with intermittent blood flow. This model may be used as an assessing tool for predicting
11

conditions where tumors may not receive therapeutic amounts of administered drug in clinical
practice, and, thus, might be inclined to resistance.
Transvascular Extravasation of Drugs
Stapleton et al52 modeled convective drug transport across tumor microvasculature and
tumor interstitium to study the transport of liposomal drug delivery that implements the
enhanced permeation and retention (EPR) effect by accounting for transvascular and interstitial
fluid dynamics.53 The model provided a theoretical framework for predicting intratumor and
intersubject variations in liposomal accumulation because of variations in EPR based on
microenvironmental physiological factors. Wu et al54 extended a previously developed vascular
tumor growth model55 by incorporating IFP and interstitial fluid flow (IFF), lymphatic drainage,
and vascular leakage. The model revealed the effects of elevated IFP on drug, nutrient and
oxygen extravasation, and tumor growth, as it indicated that interstitial pressure caused
microvascular collapse and influenced tumor growth through nutrient and oxygen deprivation.
The extravasation of molecules tends to be affected by steric, hydrodynamic and
electrostatic interactions between molecules and pores of leaky vessels. Stylianopoulos et al56
studied interactions between nanoparticles and negatively-charged pores to predict the
existence of an optimum value of surface charge density. The model was applied to various
sizes of nanoparticles and found that for every nanoparticle size, there is a value of surface
charge density above which electrostatic forces become dominant and leads to a steep increase
in transvascular flux. Such a mathematical model would play a critical role in guiding the design
of nanotherapeutic formulations for anticancer drug delivery.

12

Drug Diffusion through Tumor Interstitium
Stylianopoulos et al57, 58 modeled the tumor interstitium to predict the effects of
repulsive electrostatic interactions and fiber network orientation on the diffusion of charged
drug molecules through the matrix. Their model predictions suggested that electrostatic
interactions between fibers and drug molecules/nanoparticles tended to slow down diffusion.
This prediction explained the observation that neutral particles diffuse faster in comparison to
charged particles. Simulating fiber network orientation with varying degrees of fiber alignment,
their analysis demonstrated that the overall diffusion coefficient was not affected by network
orientation; however, diffusion anisotropy was predicted as a result of structural anisotropy.
Diffusion anisotropy becomes even more significant with increasing degree of fiber alignment,
particle size, and fiber volume fraction.
As an extension to a 3-dimensional multispecies nonlinear tumor growth model by Wise
et al.,59 Frieboes et al60 developed a model based on in vitro spheroids and monolayers of
breast cancer cells that incorporates the biophysical barriers for drug and nutrient diffusion and
provides a quantitative relationship between tumor phenotype and its response to
chemotherapy. The model simulates impeded diffusion of drug, oxygen, and nutrients, and
correlates it to poor response to chemotherapy on account of both poor drug delivery and lack
of nutrients required for cellular proliferation. The model can be instrumental for clinical use in
predicting the effect of chemotherapy on a tumor of known phenotype. Das et al61 also
modeled the 3-dimensional aspects of the tumor microenvironment in the context of the
diffusion of interferon-γ through the tumor interstitium. The mathematical model predicted the
limited success of immunotherapy in breast cancer on account of the diffusion barriers.
13

Recently, Pascal et al62 developed a mathematical model based on the physical laws of
diffusion to predict the fractional tumor killed because of chemotherapy. The important
parameters in the model were volume fraction occupied by tumor blood vessels and their
average diameter, as measured from histopathology. Drug delivery to cells and subsequent
tumor cell kill were assumed to be mediated by these microenvironmental properties. The
model predicted tumor cell kill in colorectal liver metastases and glioblastoma, using patientspecific histopathology data (Figure 1.1). Thus, it can be used to develop individualized
treatment strategies that account for the amount, frequency, and delivery platform of drugs
and other cytotoxic therapies.
Biochemical Gradients within Tumor Microenvironment
For cancer cells to remain alive and actively dividing, it is critical that their metabolic
requirements be met. When the metabolic load supersedes the supply of oxygen and nutrients,
hypoxic tumor cells tend to induce angiogenesis to maintain a constant supply of oxygen and
nutrient rich blood. Despite neovascularization, there is a continual gap between demand and
supply; aggressive tumors might have high microvascular density but still have significant
hypoxia and acidosis because of inadequate perfusion.63 Because of aberrations in the vessel
wall integrity, tumor blood tends to become hyperviscous. As a result of solid and fluid stress
within the tumor, vascular collapse can occlude the flow of blood, leading to high resistance to
blood flow and, thus, insufficient perfusion.
The distribution of tumor vasculature within the tumor is heterogeneous, creating anisotropy in
perfusion in terms of both space and time. As a result of heterogeneity of blood perfusion, drug
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does not reach uniformly to all parts of the tumor leading to a population of cancer cells being
untouched, or only moderately touched by the cytotoxic agent. Tumor tissue tends to develop
gradients of oxygen level, pH, glucose, ATP and rates of cancer cell proliferation across the
tumor. A direct implication of hypoxia is G1/S-phase cell cycle arrest.64 Because of low
extracellular pH, weakly basic drugs tend to get protonated and exhibit lower cellular uptake. 65,
66

Eventually these biochemical gradients result in reduced sensitivity to cell cycle specific

cytotoxic agents.67 In extension to a mathematical model68 that predicted the extent and
location of quiescent cells in multicellular spheroids, Venkatasubramanian et al69 incorporated
cell cycle progression, nutrient and drug transport limitations, and pharmacodynamics and
pharmacokinetics to predict the effect of tumor microenvironmental heterogeneity and
hostility on drug cytotoxicity. Their simulation results suggest a therapeutic strategy: optimizing
molecular weights of drug molecules to reach an optimum diffusion coefficient that is neither
too small to be cleared from blood before effective penetration, nor too large to limit effective
drug retention.
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Figure 1.1 Patient fraction of tumor killed regression relative to thickness of dead tissue.
Results of fitting the model62 to patient data by a regression analysis. Fraction of tumor killed
fkill and thickness of dead tumor regions rk were measured in 49 histopathologic sections of
colorectal cancer metastatic to liver after chemotherapy. Quadratic least-square fit (dashed
curve; R2= 0.92) and least-square fit (red curve; R2=0.94) of the model are shown. Biologically
realistic parameter values obtained from the fit are shown in the inset table. This analysis
demonstrates that the model agrees with the distribution of the patient data. Adapted with
permission from.62 BVF blood volume fraction, rb blood vessel radius, L diffusion penetration
distance

Overcoming Physical Barriers with Nanotherapeutics
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Current standard therapies for breast cancer are efficacious to a limited extent. 61
Nanotherapies may confer advantages over conventional drugs in overcoming therapeutic
resistance. Possible advantages include delivering higher concentrations of drug, promoting
greater drug uptake by tumor cells, overwhelming drug efflux pumps, accumulating drug in
tumor vasculature, and causing less toxic effects on the patient.70, 71 Silica nanovectors with
doxorubicin were able to overcome therapeutic resistance and outperform traditional therapies
against hepatocellular carcinoma in vitro because of their ability to carry much higher
concentrations of drug. This promoted a higher amount of overall drug uptake and greater
overall cell kill.72 Nanoparticles (NPs) also use far less drug overall, allowing for the potential to
deliver larger quantities of NPs or even higher drug concentrations with still fewer negative
cytotoxic effects.73 A study done with osteosarcoma found that NPs loaded with doxorubicin
were more effective because they had higher levels of accumulation in solid tumors and they
were able to deliver drug to the nucleus of the tumor cells.74 This accumulation may be
attributed to longer circulation times because of their small size and specific surface ligands.
These small NPs can specifically target tumor endothelium with low or high affinity, enabling
them to distribute throughout the tumor, or accumulate at the inlet, depending on which is
desired in a specific treatment.70, 71 Many researchers also contribute NPs effectiveness to its
ability to circumvent therapeutic resistance efflux pumps such as P-glycoprotein, preventing
drug loss from tumor cells.72, 74
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CHAPTER 2
MATHEMATICAL MODELING TO PREDICT RESPONSE TO NEOADJUVANT CHEMOTHERAPY USING
BREAST CANCER VASCULATURE CHARACTERSTICS

This chapter was adapted from:
Brocato, T.*; Glaberman-Brown, U.*; Wang, Z.*; Selwyn, R.; Wilson, C. M.; Wyckoff, E. F.; Lomo,
L.; Saline, J.; Pasqualini, R.; Arap, W.; Brinker, C. J.; Cristini, V. Mathematical Modeling to Predict
Response to Neoadjuvant Chemotherapy Using Breast Cancer Vasculature Characteristics.
Submitted to Science Advances. (*Authors contributed equally to this work)
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2.1 Overview
In the United States, breast cancer is the most common female cancer and is the second
most common cause of cancer death in women 75. While major advances have been achieved in
treatment of early stage breast cancer, many women still die from the disease. The use of
neoadjuvant chemotherapy has emerged as a promising approach to evaluate the efficacy of
chemotherapy in patients with early stage breast cancer. Improved patient survival is
correlated with complete eradication of invasive tumor in the primary breast lesion and lymph
nodes (pathologic complete response, pCR) by neoadjuvant chemotherapy. This has been
demonstrated in many studies, including National Surgical Adjuvant Breast and Bowel Project
(NSABP) protocol B18, in which 1,523 women with early stage breast cancer were randomly
assigned to preoperative versus postoperative anthracycline based chemotherapy 76. There was
no difference in disease-free survival (DFS) or overall survival (OS) at 5 years among either
treatment group. However, in the 683 women that received neoadjuvant treatment, outcomes
were significantly better in women who achieved a pCR compared to those without a pCR (5
year OS 87.2% vs. 76.9% - 78.4% p=0.06, DFS 83.6% vs. 60.3% -71.7% p = 0.0004) 77. Data also
support that women who have a significant response to neoadjuvant chemotherapy but do not
achieve a pCR have improved long-term outcomes. Mittendorf et al. described and validated a
novel breast cancer staging system for assessing prognosis after neoadjuvant chemotherapy on
the basis of pretreatment clinical stage (CS), estrogen receptor status and grade (EG), and posttreatment pathologic stage (PS), known as the CPS+EG score 78. The ability of the CPS + EG score
to stratify outcomes was confirmed in both internal and external cohorts, with a score of < 2
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corresponding with a 5 year disease-specific survival (DSS) ranging from 88% to 96%. In those
with a score > 3 the DSS dropped significantly, ranging from 72-88% 78.
In order to maximize the utility of the neoadjuvant therapy strategy, there is a clinical
need for tools to predict patients that are likely to respond to neoadjuvant cytotoxic
chemotherapy, thereby allowing a personalized approach to cancer treatment. Here, we
present a novel integrated study based on a mathematical model utilizing tumor vasculature
characteristics paired with patient data analysis to predict response to neoadjuvant
chemotherapy.
Response to chemotherapy is known to vary by breast cancer subtype and
chemotherapy regimen. Unfortunately, neoadjuvant cytotoxic chemotherapy with conventional
anthracycline and/or taxane based regimens (the standard of care for most patients with early
breast cancer) results in a pCR in only a minority of patients 79. For example, in SWOG 0012, 185
patients with locally advanced breast cancer were treated with standard AC (doxorubicin and
cyclophosphamide) given every 21 days for 5 cycles, followed by weekly T (paclitaxel) for 12
weeks 80. Overall pCR rate was 21%. However, in patients with hormone receptor (HR)-negative
tumors, the pCR rate was 29% compared to 11% in patients with HR-positive tumors. Tumor
specific biomarkers predicting response have been explored, including tumor infiltrating
lymphocytes (TILs). TILs correlate with improved outcomes in several cancer types, including
colorectal, ovarian, esophageal, renal, lung, pancreatic, and breast cancer 81-83. The presence of
TILs in diagnostic needle core biopsy in women with early stage breast cancer was shown to be
an independent predictor of response to neoadjuvant chemotherapy 84, as was TIL density 85.
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We hypothesize that tumor vasculature characteristics may similarly be a biologic
predictor of response to chemotherapy. This hypothesis was previously examined in a series of
integrated modeling studies evaluating the prediction of cancer treatment outcome based on
drug diffusion and physical properties of the tumor 72, 86-92. We hypothesized that diffusion
barriers prevent drugs from reaching the tumor, a mechanism that (among others) underlies
drug resistance 93. Our mechanistic mathematical model for predicting tumor response to
chemotherapy (denoted by fkill, i.e., the fraction of tumor killed due to therapy) has been
validated retrospectively in patients with colorectal cancer (CRC) metastatic to the liver 86. The
model has demonstrated the ability to predict tumor response to chemotherapy treatment
using three drug perfusion and diffusion related histology parameters: blood volume fraction
(BVF) in the tumor, the distribution of blood vessels (rb), and the drug diffusion distance in
tumor tissue (L). These three parameters are tumor and patient specific, and therefore need to
be measured on an individual basis. Additionally, pre-chemotherapy contrast-enhanced
computer tomography (CT) perfusion scans were used to calculate the model parameters,
followed by correlation of model predictions to post treatment results. We observed an
average relative error of ~15% when comparing fkill predicted from histopathology vs. fkill
predicted from pre-treatment CT-derived patient specific BVF values. Here, we sought to
expand on this model by applying it to breast cancer, evaluating histology and dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) data. It is worth noting that, in the
previous retrospective study 86, two major parameters (rb and L) were solved for in the fkill
model; whereas, in the present study, all model parameters were directly measured using a
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semi-automated computer program further described below. See Figure 2.1 for an overview of
our research protocol.

1. Apply math modeling to Cohort A to identify primary resected whole tumor
parameters
• Cohort A: 30 patient with primary resected breast cancer (10 ER/PR+, 10 HER2+, 10 TN)
• Measure tumor parameters: blood volume fraction BVF, blood vessel radius rb, and
diffusion distance, L, and calculate ƒkill using Eq. 2.2
• Evaluate model parameters by ER, PR, and HER2 status

2. Apply math modeling to Cohort B core biopsy samples as a surrogate for
whole tumor analysis
• Cohort B: 18 patients treated with anthracycline/taxane based neoadjuvant
chemotherapy (10 prospective and 8 retrospective patietns, HER2-)
• Measure tumor parameters from core biopsy samples: blood volume fraction BVF,
blood vessel radius rb, and diffusion distance, L, and calculate ƒkill using Eq. 2.2
• Obtain pre-treatment perfusion measurements by diffusion contrast MRI as a proxy of
tumor parameters.

3. Apply model
• Evaluate post-neoadjuvant chemotherapy clinical reposne in Cohort B patients at the
time of surgery, including CPS+EG clinical scores and pCR
• Correlate ƒkill with pCR and CPS+EG score
• Correlate MRI results with response and histology results

Figure 2.1. Research protocol.
2.2 Results
Needle Core Biopsy Feasibility
We first sought to determine the feasibility of using diagnostic needle core biopsies to
mathematically predict fkill in women with stage II-III HER2- breast cancer infiltrating ductal
carcinoma receiving neoadjuvant anthracycline/taxane based chemotherapy. Toward this goal,
histological analysis to obtain model parameters was performed retrospectively on whole
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tumors from 30 patients who underwent upfront lumpectomy (primary surgery without prior
systemic therapy), Cohort A in Figure 2.1. Model parameters obtained from the whole tumor in
these patients were subsequently compared to a similar analysis of histologic samples from 18
patients’ pre-neoadjuvant chemotherapy diagnostic needle core biopsy, Cohort B in Figure 2.1;
the results are shown in Figure 2.2. Nonlinear regression was performed using the fkill model
and patient histological parameters specific to each patient’s tumor vasculature. Cohort A has a
higher BVF than Cohort B likely due to the whole tumor section analysis in Cohort A, while
Cohort B had of the more limited core biopsy samples. Due to shape alone, the tissue section
from a whole tumor block results in a larger highly vascularized tissue region (perimeter of
tumor) for Cohort A when compared to the cylindrical shape of a core biopsy for Cohort B. The
patient samples for both cohorts fall along the same regression line; correlation for Cohort B
analysis between fkill(BVFbiopsy, (L/rb)biopsy) vs. fkill(BVFbiopsy, (L/rb)fitting) results in r = 0.7042. This
demonstrates that core biopsy samples can be used to determine histological parameters
representative of the whole tissue region. Subsequent analysis demonstrated that L/rb
measurements provide significant distinction between patients in Cohort B achieving a pCR and
those without a pCR, Figure 2.3.
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Figure 2.2. Model analysis. Cohort A: 30 retrospective patients undergoing primary surgery
without prior systemic therapy analyzed using histology semi-automated analysis and
mathematical model. Cohort B: 18 patients receiving neoadjuvant chemotherapy are shown to
distinguish patients with pathologic complete response (pCR) vs. those without a pCR. Each
point is a patient’s predicted fkill using averages of BVF, rb, and L measured directly from
surgically resected tumor tissue stained with CD34 by immunohistochemistry. The black line
shows an fkill regression line calculated from Eq. 2.2 with optimized parameter L/rb = 13.6981, R2
= 0.79875. The fkill regression line includes fitting of all treated and not treated patients (n = 48).
Error bars are calculated based on error in BVF measurements and their respective variation
that it causes when plugging into the fkill equation (Eq. 2.2).
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Receptor Status Non-Separation between Patient Groups
There was no differentiation between patient groups (hormone receptor positive
tumors, HER2 positive, and triple negative breast cancer) in the Cohort A based on an ANOVA
test. These patients are thus grouped together for fkill mathematical modeling, as shown in
Figure 2.2.

Clinical Scoring System and Separation between Clinical Outcomes by L/rb
CPS+EG scores range from 06, where patients having a CPS+EG < 2 have a 88% chance
of being alive 10 years following diagnosis 78. We were unable to discriminate between
responders and non-responders using a CPS+EG score of < 2. However, analysis of histology
measurements, specifically L/rb, provides a separation of patients achieving a pCR from those
that do not, with 80% accuracy shown in Figure 2.3. A positive correlation is seen between pCR
and L/rb, validated in Figure 2.5. A t-test on L/rb between pCR and no-pCR patients indicates p=
0.0269 (significance level α = 0.05, two-sided parametric test, assuming equal variances). A
single patient was identified as a clear outlier, potentially as a result of a dense population of
TILs, (a known independent predictor of response to neoadjuvant chemotherapy, although not
all patients in Cohort B with TILs had a similarly positive responses to therapy. By model
parameters, this patient was predicted to not have a pCR. We note that this benchmark L/rb
value is likely to be cancer-type specific, the determination of which would require the
evaluation of a lager patient cohort.
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Figure 2.3. Histological parameters and their correlation. pCR and L/rb demonstrate a positive
correlation. Dashed grey line based on L/rb (approximately 20) separates patient groups with
80% accuracy.

DCE-MRI Area under the Curve (AUC) Association to Histology L/rb
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Figure 2.4. DCE-MRI regions of interest (ROIs) for incorporation into Figure 2.5. Image shown is
an Area Under the Curve (AUC) Map for all MRI time points for which data are taken, 0-5.5
minutes, with all Regions of Interest (ROIs) being spherical. All hotspot ROIs are defined as the
max 1cm3 spherical ROI with the center point included in the main ROI drawn. Ipsilateral ROI is
shown as an alternative control ROI if both breasts on the patient contain a tumor, in this case
the Ipsilateral ROI Hotspot will be used in place of the AUC Contralateral ROI hotspot.

AUC

AUChotspot(tumor/control) = AUC

Tumor ROI hotspot

[Eq. 2.1]

Contralateral ROI hotspot

Figure 2.5. Response to neoadjuvant chemotherapy and DCE-MRI in Cohort B. CD34 stained
core biopsy samples measured for L/rb (radius of blood vessel: rb, tissue diffusion penetration
distance: L) and its relation to DCE-MRI area under the curve (AUC) analysis, time points 0 - 5.5
minutes, taken for the hotspot region of the tumor normalized to the contralateral breast’s
hotspot in the same tissue region on the contralateral breast (considered to be normal breast
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tissue). Coefficients A, B, and k are fit to determine best values for prediction between L/rb and
its relation to DCE-MRI area under the curve (AUC) analysis using a reciprocal function. A, B,
and k are coefficients specific to stage HER2 negative, stage II-III breast cancer treated with
neoadjuvant treatment.
Histology and DCE-MRI measurements demonstrate a link shown in Figure 2.5, and an
example for where the data comes from in Figures 2.4 (Eq. 2.1) and Figures 2.7. As described,
diagnostic core biopsy samples were analyzed to obtain L/rb. pCR and L/rb demonstrate a
positive correlation which is demonstrated in Figure 2.3 additionally. An area under the curve
map (AUC) in the tumor region was used to estimate tumor blood perfusion from DCE-MRI
data, as previously demonstrated in Pickles et al 94. In order to obtain quantitative data from
DCE-MRI, a region of interest (ROI) must be used; here, the hotspot of the tissue ROI (tumor or
control tissue) was used to determine the max perfusion in that tissue region. Tissue hotspot
analysis has been shown to be a good predictive tool for DCE-MRI 94, and was demonstrated to
be predictive of treatment outcome short-term (AUC map of hotspot 3x3 pixel region) when
looking at pre-treatment and early in treatment 94, 95. By correlating AUC obtained from MRI
measurements to L/rb obtained from histology, we can better predict which patients will have a
response to neoadjuvant chemotherapy prior to getting treatment. Furthermore, this can be
performed without using core biopsy samples, useful given the often limited specimens
obtained at the time of biopsy.

2.3 Discussion
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The work presented here demonstrates that it is feasible to evaluate predictive
biomarkers, specific to primary breast cancer vasculature in a patient specific manner, using
semi-automated analysis. The quantities: rb, BVF, and L are shown to be reliably predictive of
tumor fkill when obtained from either mastectomy/lumpectomy specimens or diagnostic needle
core biopsy in stage II-III breast cancer patients.
One of the limitations in our previous research in CRC 86 was that the histology
parameters, L and rb were solved for in the fkill model (Eq. 2.2). Here, we have updated this
method by measuring these values (L, rb, and BVF) directly from histology. BVF was previously
measured from hematoxylin and eosin stained slides 86. In the current study, we utilized
vasculature specific staining to allow for better visualization, increasing the accuracy of analysis.
Measurements were previously done by hand which is prone to human error. In the present
study, a semi-automated computer program was created to allow for increased accuracy in
measurements while reducing time required for analysis. The automated analysis allows for
rapid throughput; in this study over 4000 patient images were analyzed. Furthermore, in this
study we correlated clinically relevant treatment response assessments (pCR and CPS+EG) with
model parameters measured. Some limitations of this study include differences in vasculature
staining, which was minimized using a computer automated staining protocol, additionally
tissue staining was performed in the minimum number of staining batches possible. Core
biopsy samples are taken through one entrance point, which may limit the tumor region being
tested. Attempts are made to take into account such tumor heterogeneity by taking 3-4
biopsies which extend out from the entrance point. Additionally, patient clinical DCE-MRIs
should contain a normalization method during acquisition to allow for a controlled method for
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all patient MRIs with T1 mapping and magnetic field correction additionally with scans taken
frequently (every 3 seconds and more spaced out between scans for 90 seconds through 5.5
minutes post contrast). In order to obtain a BVF from MRI, at the time of scanning, arterial
input function might be evaluated to obtain additional data from the MRI and make core biopsy
histology not necessary for model prediction.
Tumor vasculature is a chaotic labyrinth of malformed and destabilized vessels that are
structurally and functionally impaired 96. Jain et al. has argued that drug delivery to tumors can
be enhanced through tumor vessel normalization and reduced interstitial fluid pressure
induced by anti-angiogenic therapy 50. A low L/rb value for pCR patients is indicative of a more
“normalized” baseline tumor vasculature, explaining improved response to chemotherapy in
this subset of patients. Normal tissue has regularly spaced (or separated) blood vessels which
increases the value L, and therefore lowers the L/rb parameter. Patient tumors with a high L/rb
values tended to have “pooled blood”, or regions with highly vascularized tissue, severely
limiting blood and drug delivery to poorly vascularized tumor regions.
DCE-MRI analysis resulted in AUC providing the most information regarding patient
response from the data set provided. Hotspot ROI AUC analysis provided the best correlation to
treatment outcome, when compared to looking at the whole tumor using 3D spherical ROI and
a tumor ROI. Thus, the greatest perfusion region seems to be the best predictor of treatment
outcome. Although hotspot analysis dictates outcome, the average tumor analysis typically
leads to the same conclusion as well. Application of this model for clinical use at an initial
diagnostic stage will allow for non-invasive prediction of tumor outcome, whereby likelihood
pCR can be estimated early in the course of treatment, using flowchart Figure 2.6.
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Prediction of Treatment Outcome
Dynamic contrast-enhanced MRI
Classify patient based on MRI and L/rb via histology
pCR not predicted

pCR predicted

Novel therapy /
clinical trial

Standard neoadjuvant
chemotherapy

Figure 2.6. Prediction of treatment outcome flowchart using both MRI and tumor histology
from diagnostic biopsies.

Our next steps will expand upon these results through inclusion of more MRI
measurements with additional time points, including MRIs that will be taken after the patient’s
second neoadjuvant chemotherapy treatment. This is expected to provide a tool to determine
early on if the patient is likely to responding to standard treatment, allowing personalized
therapy. We also plan to investigate if and how we can use MRI as a surrogate for histology in
the mathematical model parameters to predict treatment outcome.

2.4 Methods and Materials
Patient Cohorts.
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Patient cohort A: 30 patients who underwent upfront surgical resection for invasive
adenocarcinoma of the breast (without prior systemic therapy). 10 hormone receptor positive
tumors (ER/PR+), 10 HER2 positive (HER2 amplified) tumors (HER2+), and 10 triple negative
tumors were selected for retrospective histological analysis. See Histology and Histology Semiautomated Analysis sections below.
Patient cohort B: 18 women with HER2 negative stage II-III infiltrating ductal carcinoma of the
breast receiving neoadjuvant chemotherapy with modern anthracycline / taxane based
chemotherapy. 10 patients were treated and evaluated for model parameters prospectively,
with an additional 8 patients evaluated retrospectively. Final analysis of the 18 patients was
performed in aggregate. 6 of 18 patients had hormone receptor positive tumors, while 12
patients had triple negative tumors. Pre-treatment diagnostic core biopsy was used for
Histology Semi-automated Analysis (see below for details). Pre- and post-treatment magnetic
resonance imaging was performed per standard of care. All patients received a standard of care
neoadjuvant chemotherapy regimen containing both an anthracycline and a taxane. Following
treatment, the patient’s clinical outcome was evaluated (see Patient Outcome Evaluation).
Patient Outcome Evaluation. Patient treatment response was determined after completing
neoadjuvant chemotherapy. Resection specimens were analyzed for pCR (yes / no). In addition,
patient treatment outcome was measured based on the CPS+EG score 78. All patient treatment
outcomes were determined by a pathologist.
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Magnetic Resonance Imaging. Patients had pre-treatment and post-treatment gadolinium
dynamic contrast-enhanced magnetic resonance imaging (MRI) on 3T MRI which was used as an
imaging additional method to determine tumor and breast tissue perfusion. Scans were taken
pre-contrast, and post contrast at 90 seconds, 3.5 minutes, and 5.5 minutes. Patients with MRIs
not conforming to this criteria were excluded from the MRI Analysis.
MRI Analysis. Analysis of MRI data was performed using OsiriX DCE Tool Plugin 97. Area under
the curve was measured using a 3D spherical ROI over the tumor region determined by a
radiologist, and the hotspot (maximum signal in a 1 cm3 region given the original ROI) was
measured for the tumor. A control ROI the same size as the tumor ROI was used on the
contralateral breast, in the same general anatomical position as the tumor and used for
normalization, as this is considered to be a baseline for the individual patient’s normal tissue
vasculature. See Supplementary Figure 2.7 for MRI image examples and analyses performed.
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Figure 2.7. Dynamic contrast-enhanced magnetic resonance imaging axial view. A) Before
contrast agent was injected, B) 90s post-contrast, C) 90s post-contrast with regions of interest
(ROI) colored in red (tumor), yellow (normal tissue on isolateral breast), blue (normal tissue on
contralateral breast). Note the smaller orange ROIs associated with the red and yellow ROI,
these are 1cm3 “hot spots” (maximum signal given the original ROI) D) area under the curve
map, analysis in Figure 2.5 was obtained from this map with the ROIs shown in C E) Tumor ROI
shown in 3D view, F) area under the curve map signal intensity scale.

Histology. Patient tissue samples were formalin-fixed and paraffin embedded, and processed
per institutional standard of care, in compliance with ASCO-CAP guidelines. The Human Tissue
Repository and Tissue Analysis Shared Resource at the University of New Mexico’s Cancer
Center served as an honest broker for access to all tumor specimen. CD34 antibody staining via
immunohistochemistry was used to highlight tumor vasculature. Additionally, hematoxylin and
eosin stain was performed to evaluate tissue morphology (e.g. tumor, non-tumor)
Histology Semi-automated Analysis. Patient histological samples from patients Cohort A, and
patient core biopsy samples from patients Cohort B were analyzed using HALO image analysis
software (Indica Labs) to separate out tissue regions from the CD34 stained tissue sections:
CD34+ tissue regions (vasculature), CD34- tissue regions (non-vasculature tissue), and
background regions (non-tissue). HALO uses machine learning to classify tissue regions based
on a training set. Tissue regions were separated into 1x1 mm2 square regions for analysis using
code developed in Matlab (MathWorks). The code developed takes the separated regions
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(separated by HALO) and measures vasculature radius, rb (µm), measured along the short axis of
the vessel; short axis is used due to the consideration that the vessel could be in the plane of
the tissue section. See Figure 2.8 for outline of analysis. Multiple measurements were taken for
each vessel to get an accurate measurement of radius for each vessel with an average taken for
an rb value for each grid analyzed. The blood volume fraction, BVF, was taken to be the
vasculature area (in red) divided by the whole tissue region (blue + red in Figure 2.8C). Only
tissue regions were considered for BVF measurement. From the perimeter of each vessel, the
maximum distance drug/blood/nutrients would have to diffuse to feed the whole tissue region
is calculated and shown at each point in black. All distances to nearest vessel (in red) are taken
and averaged for each grid analyzed to get the diffusion penetration distance, L, measured in
µm.
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Figure 2.8 Diffusion analysis schematic. A) Shows the original CD34 stained histology grid
before any processing. B) Displays the same tissue region as in A, but with the outer inked
portion removed due to the increased likelihood of false positives on the perimeter of core
biopsy samples (the pathology department inks tissue cores for quality purposes). C)
Demonstrates a computerized version of B and differentiates between tissue CD34 - (blue),
vasculature CD34+ (red), and non-tissue regions (grey). D) Shows the diffusion analysis of image
C, which was performed by code developed in Matlab. Average measurements taken for the
image are: vessel radius (rb), blood volume fraction (BVF), and diffusion distance (L). Vessels are
outlined in red, and total area of blood vessels in a tissue region is blood volume fraction, BVF.
Radius of blood vessels which are measured at each blue point inside of a vessel (outlined in
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red). An average of all vessel radii in each image analyzed is taken to be rb (µm). The farthest
distance nutrients or drug need to travel from a vessel to reach all tissue, the distance from that
point to vessel in red is measured at each point in black, all distances averaged is the diffusion
penetration distance, L, measured in µm. White is the tumor tissue region, all of which is
considered for analysis. Green is the background/non-tissue region not considered for analysis.

Mathematical Model.

f kill  2  BVF 

BVF K1 (rb L)  K1 (rb ( L  BVF))
BVF  rb / L  K 0 (rb L)  (1  BVF)

[Eq. 2.2]

fkill equation with parameters rb, BVF, and L, which are directly measured from histology semiautomated analysis. fkill is the fraction of tumor cells killed in a patient predicted as a function of
the other parameters on the right side of the equation. rb is the average radius of blood vessels
in the tissue section analyzed. BVF is the fraction of blood volume in the tumor. L is the farthest
distance nutrients/drug need to travel from a vessel to reach all tissue 86.
Statistics Analysis and Graphing. Matlab and GraphPad Prism 7 were used to determine best fit
using patient averages for BVF, rb and L placed into Eq. 2.2 and using non-linear regression
solving for L/rb ratio. Fits were obtained using initial values for fit, L/rb = 20 and L/rb > 0.005 for
a constraint.
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CHAPTER 3
NANOPARTICLE UPTAKE AND CANCER TREATMENT EFFICACY MODELING

This chapter was adapted from:
Brocato, T.; Coker, E. N.; Durfee, P. N.; Lin, Y. S.; Townson, J.; Wyckoff, E. F.; Cristini V.; Wang, Z.
Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy
using Mathematical Modeling. Submitted to Nanomedicine: Nanotechnology, Biology and
Medicine.
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3.1 Overview
Cancer represents the 2nd major cause of death in the United States, and one out of
eight women is estimated to develop invasive breast cancer in her lifetime 98. Breast cancer
tumors are heterogeneous, and the series of events which cause them to grow, shrink, or
metastasize are complex, involving interactions with and influences from their
microenvironment 99. It is known that the heterogeneity of the breast cancer tumor greatly
complicates our understanding of the disease and the development of effective treatment 99. In
fact, most tumors are heterogeneous both phenotypically and functionally 100, resulting in
variable traits among different tumors. Understanding an individual’s response based on these
differing traits is essential for predicting and improving patient-specific treatment response.
Due to drug toxicity and non-specificity, a spectrum of different particles have been
developed for both particle-based drug delivery and for imaging of particle distribution,
including superparamagnetic iron oxide nanoparticles 101, lipid bilayer encapsulated
nanoporous silicon or mesoporous silica particles for drug/cargo delivery 102-104, and silica based
nanoparticles 105, to name a few. Here, we discuss the use of mesoporous silica nanoparticles
(MSNPs), which possess the benefits of a high cargo capacity, due to their immense internal
surface area (800-1000 m2/g), facile surface modification to enable targeting, low toxicity,
therapeutic effectiveness 106, 107, and increased circulation time, therefore increasing total
tumor drug uptake 107. As a result, the effective therapeutic drug dosage is reduced when
delivered using MSNPs relative to the free drug delivery case, minimizing treatment side
effects.
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Using an integrated mathematical modeling and experimental approach, our group has
shown that nanocarrier mediated drug delivery of doxorubicin achieves equal cell kill efficacy at
a dose only 20% of that of the corresponding free doxorubicin in a hepatocellular carcinoma
cell model in vitro. In the present study, we use 50-nm diameter acetylated MSNPs, modified
with polyethylene glycol (PEG) and polyethyleneimine (PEI) as first reported in Townson et al. 103
These acetylated MSNPs were found to be colloidally stable and non-toxic. They were shown to
have reduced non-specific binding to cell types A549, A431, Hep3b and hepatocytes in vitro, as
well as to endothelium and white blood cells, and were observed to remain in circulation over 6
hours post injection in a chorioallantoic membrane (chicken embryo) model 103. The increased
circulation time of the acetylated MSNPs (> 6hrs) greatly improves their likelihood of entering
the tumor and delivering effective drug dosages to cancer cells when compared to the
circulation time of free drug (<2 hrs, t1/2 = 1.68 hrs) 6.
A number of techniques have been developed to monitor the pharmacokinetics and
biodistribution of nanoparticles in living animals, including optical fluorescent microscopy
imaging 108-110, ultrasound 111, in vivo bioluminescence (IVIS® using luciferase) 112-114, and PET,
SPECT, and CT (as well as combinations of these techniques) using appropriate contrast agents
108, 109, 115-117.

However, successful prediction of treatment outcome based solely on parameters

measured from the biodistribution of nanoparticles is challenging because the distribution of
nanoparticles and of drug are different and heterogeneous across tissues, organs, and even
whole organisms. We have previously developed a mathematical model72, 118 that predicts the
fraction of tumor killed by chemotherapeutic treatment (denoted by fkill) based on drug uptake
and nanoparticle drug flux. fkill was shown to be quadratic with respect to time, especially in the
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initial phase of a treatment. In the present study, we seek to expand upon this model72, 118 in
order to develop a mathematical theory to predict nanoparticle-based treatment efficacy based
on quantitative data obtained from measured nanoparticle biodistribution.
Measurement of drug distribution in vivo is often difficult and expensive. Typically,
quantitative analysis of nanoparticle biodistribution is done through organ dissection after
injection of labeled nanoparticles, followed by imaging, using methods such as transmission
electron microscopy or optical microscopy, or by elemental analysis using inductively coupled
plasma-atomic emission 119. Nanoparticle distribution can also be measured in vivo using
magnetic resonance imaging and magnetic particle imaging 119. Here, capitalizing on the low
natural abundance of elemental silicon in mammals, we performed Si elemental analysis of the
major organs in order to measure MSNP concentrations, and then compared these quantified
MSNP accumulation values to changes in tumor volume. By using our theory to link measured
tumor growth with nanoparticle distribution and concentration, and considering the effects of
vasculature and diffusion characteristics, we were able to successfully predict the in vivo
therapeutic efficacy of MSNP-delivered doxorubicin to 4T1 breast cancer tumors in mice.

3.2 Results and Discussion
Cancer stage at the time of diagnosis is demonstrated to be an important predictor of
morbidity and survival 120. Five-year survival rates for breast cancer are 99% when diagnosed
pre-metastasis, but with a significant reduction to only 25% five-year survival rate when the
tumor has metastatized 120. In order to better understand the difficulties of effective theraputic
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treatment when patients are diagnosed at a later stage, our experiments focused on treating
tumors that were relatively large with distant metastases prior to the start of a treament.
Accordingly, we implemented a 4T1 cell line experiment in BALB/c mice, in order to study stage
IV human breast cancer with metastasis in the presence of an active immune system.
Treatment efficacy between MSNPs loaded with doxorubicin (Dox) and free Dox was
compared at the same dosage; phosphate buffered saline (PBS) was used as a control in a third
treatment group. Tumor size measurements in mm3 are shown in Figure 3.1 for three groups of
seven mice each treated using PBS (control), free Dox, or MSNPs loaded with Dox. Due to this
treatment being adminstered at a later stage of breast cancer, it can be observed that free Dox
treatment is not effective at a late stage; but the nanoparticle treatment shows some efficacy.
This late stage study confirms that MSNPs loaded with Dox exhibit a better treatment outcome
than the other treatment groups, indicating Dox loaded MSNPs are more effective than Dox
administered alone.
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Figure 3.1. Average tumor volume measurements. Three treatment groups (7 mice/group):
PBS (control), free doxorubicin (Dox), and 50nm MSNPs loaded with Dox. Each group’s average
tumor size is shown above. Measurements were taken on days 0, 3, 7, 8, and 9. Treatments
were given on days 0, 2, 4, and 7.

In vivo biodistribution of nanoparticles based on size, shape, composition, and surface
characteristics is still not well understood, as are the details of nanoparticle removal from
circulation by the reticuloendothelial system 121. To gain a better understanting of these
important parameters, we used graphite furnace atomic absorption (GFAA) to measure silicon
(Si) concentration and distribution within tissues of interest 122. The Si concentration in the
control (PBS) group was used as a baseline for the background Si concentration which occurs
naturally in tissues (Si has important biofunctionality, and thus is found in trace quantities in
many tissues). As expected, we observed that the amount of naturally occurring Si in the
control tissues was low relative to the signal of MSNP in treated tissues (Figure 3.2, control).
Figure 3.2 shows measured values of elemental Si determined by GFAA, presented as the mass
percentage of Si in the corresponding tissue being tested in mouse organs from the control and
Dox loaded MSNP treatment groups after 9 days of treatment and sacrifice. The tissues tested
were tumor, kidney, liver, spleen, as well as a measured sum of all organs. The sum of all organs
tested corresponded to ~24.4% of the total injected Si dose, as shown in supplementary
Figure 3.4.
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Figure 3.2. MSNP deposition (Si mass %) in liver, spleen, kidneys, tumor, sum of organs, and
average Si concentration naturally in tissues (control group) taken post-sacrifice (day 9). Data
were obtained using GFAA spectrophotometry. Error bars are calculated based on the standard
additions method used to calculate Si concentrations.
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Figure 3.3. Tumor delivery efficiency (%ID). Data were obtained using GFAA spectroscopy.
Absolute Si mass % in tumor was subtracted from naturally occurring Si measured by testing
control tumors in mice not exposed to MSNPs. Delivery efficiency is Si mass % in each tumor
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Figure 3.4. Delivery efficiency (%ID) in liver, spleen, kidneys, tumor, and sum of organs. Data
were obtained using GFAA spectroscopy. Absolute Si mass % in organs were subtracted from
naturally occuring Si measured by testing control mice not exposed to MSNPs.

Mice, even within the same treatment group, demonstrated a wide range of fkill
responses, indicated by the large standard deviation seen in tumor volumes in Figure 3.1 (error
bars). Moreover, the concentrations of Si deposited in the liver, spleen, kidney, and tumor were
shown to vary without correlation between uptake in the tissues measured (Figure 3.2). For
example, mice that had greater MSNP uptake in the liver did not have greater or lesser uptake
in the tumor, see Figure 3.3 for tumor delivery efficiency (%ID), and mice with less MSNP
uptake in the tumor did not have less or more uptake in other organs. From our experiments
here, we find that the MSNP delivery efficiency to the tumor is about 0.22%ID on average.
Based on an extensive review of papers over the past ten years, Wilhelm et al reports 0.7%ID as
being the average tumor delivery efficacy using a multitude of particles, cancer types, and
measurement methods, and mentions that, “it is possible that the amount of nanoparticles
reaching cancer cells and their subcellular compartments in vivo is much less than 0.7%ID
because nanoparticles need to cross the tumour extracellular matrix to reach the cancer
cells.”123 Hence, our data seems well consistent with Welhelm et al’s paper. One paper used
elemental analysis, ICP-AES, to measure silica nanoparticle concentration, of which the %ID was
determined to be 0.29, 1.6, and 10.8%ID124, most of the quantifications used to calculate the
average of 0.7%ID in a tumor used PET scans as a method of quantification 110, 116, 125, 126. Thus,
the biodistribution of nanoparticles was observed to show significant variability, even amongst
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similar mice under the same treatment protocol. Blood volume fraction (i.e., the volume of the
tumor occupied by blood vessels) was previously shown to be an important factor in predicting
fkill in human colorectal cancer metastasized to the liver 86.
Many current nanoparticles have achieved the capability to release drugs at a nearly
constant, sustained rate for a period of days, weeks, or even months 127-129, although this rate
may be dependent on other physiochemical properties of the particles, such as the surface
chemistry and pore size 130. In vivo, this nearly constant drug release rate results in an
approximately unchanged rate of change of drug flux (denoted by F) across blood vessels. By
further assuming a linear drug uptake by cancer cells, we have devleoped a special form of fkill
for predicting treatment efficacy for nanoparticle-based drug delivery systgems 118. We found
that tumor response in vivo to Dox loaded nanoparticles occurs quadratically over time, at least
for the first several days (Eq. 3.4; also see Methods), and have further validated this model
using experiments on a breast cancer mouse model. Accordingly, we used this quadratic tumor
response model to link the MSNP deposition with measured changes in tumor volume (relative
to control). The quadratic tumor response coefficient (i.e., fkill coefficient: ϴf) was determined to
have an exponential relationship with MSNP deposition in the tumor tissue (Figure 3.5). ϴf was
found to be predictable based on tumor silicon content with 95% confidence (R2 = 0.817, p.05 =
0.0007). This indicates that increasing chemotherapy drug delivery, using a MSNP transport
vector, results in an exponentially greater rate of tumor kill. Values for comparison are shown in
Table 1, along with statistics that indicate that most model values are statistically significant at
95% confidence except for MSNP 5. MSNP 4 and 7 did not show measurable response to
treatment until day 7, resulting in only two data points; therefore, p-values for ϴf could not be
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determined due to an insufficient number of points. As such, these two mice were removed
from further analysis. Together, this indicates that MSNP uptake is an important factor in
determining tumor treatment efficacy. However, more tumor measurements and/or a longer
experiment would be beneficial to validate statistical significance with the model predictions.

Table 3.1. Tumor fkill coefficients (ϴf), as described by Eq. 3.4, show a similar order to Si
deposition values. The Si deposition values are also shown in Figure 3.2 (MSNP deposition) and
in Figure 3.5 (R2, ϴf, t0), showing the exponential relation to the tumor fkill coefficient calculated
using Eq. 3.4.
Mouse

Si % in
tumor

MSNP 4
MSNP 7
MSNP 2
MSNP 3
MSNP 1
MSNP 5
MSNP 6

0.00513
0.00535
0.00372
0.00362
0.00360
0.00138
0.00260

t0 (time tumor begins
to respond to
treatment in days)
0
0
0
0
0

ϴf (quadratic
response
coefficient)
0.4621
0.3068
0.0096
0.0067
0.0064
0.0027
0.0013

48

p-value

R2
(quadratic)

0.0030
0.0050
0.0110
0.1990
0.0060

0.9648
0.9499
0.9155
0.4728
0.9409

Figure 3.5. Si concentration and fkill coefficient (ϴf) determination. ϴf, explained in Eq. 3.4, is
predicted based on tumor Si absolute mass percentage in tumor, as measured using graphite
furnace atomic absorption (GFAA). R2 = 0.817, p.05 = 0.0007 for quadratic fkill coefficients
calculated after 9 days of treatment and sacrifice. This was determined by the best fit between
fkill and Si concentration using an exponential fit (which represents the best fitting function
among many we have tested, including linear and nonlinear functions, e.g., the Hill function).
Experimental mouse tumor fkill was determined using Eq. 3.2 for mice treated with MSNPs.
Model mouse tumor fkill was determined by optimizing values for t0 (days in integer values),
described in Eq. 3.4.
We then performed correlation analysis to compare model results (computed as
f kill  0.000172  e1664.39 Si  t 2 , where Si is tumor Si mass %) and the corresponding time course MSNP

experimental data, as shown in Figure 3.1. We obtained correlation coefficient r = 0.89 and p <
0.001, and thus consider the model to be acceptable in predicting MSNP-based treatment
outcome with absolute Si mass percent as input.
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Cancer treatment can be improved greatly by using MSNPs as chemotherapy delivery
vessels, which allow for an increased effective drug dose to be delivered to the tumor site due
to drug sequestration within the particles during transit to the site, resulting in reduced uptake
by the reticuloendothelial system and longer circulation time 131. We have provided further
insight into this drug delivery system using MSNPs in a murine 4T1 in vivo tumor model
combined with a mathematical modeling description of drug efficacy. In particular, our
mathematical model demonstrates that an increase in MSNPs delivered to the tumor
exponentially increases the cell kill at early times in the treatment, leading to improvements in
overall treatment outcome. The major hurdle is thus increasing tumor MSNP delivery over
current methods, as any increase in delivery to the tumor is expected to significantly improve
treatment efficiency. In this perspective, active tumor targeted delivery of chemotherapy via
targeting ligand modified nanoparticles102, 132 is expected to enhance treatment efficacy.
Morover, if the quadratic fkill coefficient could be determined early on, the treatment
efficacy could be predicted by our mathematical model. It has been demonstrated that tumor
exponential growth rate constants were correlated to patient survival 133. Here, we demonstate
that, due to external stresses and regression in tumor size due to treatment, the quadratic
coefficient following treatment is predictive of treatment uptake and therefore treatment
efficacy. Note that ϴf is a combination of parameters, inlcuding drug flux across blood vessels,
cell death due to accumulated drug, and initial tumor volume (see 118 for details). This implies
that ϴf may have a nonlinear relationshiop with Si content, which has been confirmed in this
study where an exponetial relation was found. In future efforts, a better understanding of
nanoparticle biodistribution behavior will allow us to have a more adaptive use of the model
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presented here. Additionally, further model validation against information obtained from noninvasive imaging modalities such as MRI, PET/CT 134 will help to quantify nanoparticle-based
treatment outcome without the need to sacrifice animals. This important next step will also
progress the model towards a more clinical functionality, where it may be implemented as a
predictive tool without the need for invasive diagnostic procedures.

3.3 Materials and Methods
Mathematical modeling. We recently developed a series of mathematical models in closed
form for predicting tumor response to treatment based on time- and space-dependent drug
diffusion and perfusion properties 61, 72, 86, 88, 89, 91, 118. A generalized model presented in 118 can
provide predictions of outcome for both conventional chemotherapy with a specific dosing and
timing regimen and nanoparticle-based treatment. fkill (i.e., the fraction of tumor killed by
treatment) is defined as:

f kill  1 

Vi  t 
,
VC  t 

(Eq. 3.1)

where V is tumor volume at time t, i indicates drug treatment group, and C indicates the control
group. Normalizing tumor volume at a given time t to initial volume, we have

f kill  1 

Vi  t  / Vi  t0 
,
VC  t  / VC  t0 

(Eq. 3.2)

where t0 is determined to be the initial day when treatment was started; in our analysis here, i
simply indicates either free DOX or MSNP treatment group.
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Assuming that drug-loaded nanoparticles can accumulate within tumors and continuously
release drugs at a nearly constant rate over a certain time interval (especially at the initial
phase of a treatment), we derived a special form of fkill 118:

f kill 

F  λk 2
t ,
2VT,0

(Eq. 3.3)

where F is the flux of drug across blood vessel walls, 𝝀k is the death rate of tumor cells, VT,0 is
the tumor volume when tumor begins to respond to treatment (positive fkill), and t is time. Note
that there is another key assumption we made to the original fkill model, which is composed of a
system of differential equations, in order to develop this simplified form: a drug administered
as bolus at a certain dose level has the same effect as the same total amount of drug
administered over several months at a constant, smaller dose level 91. That is, this model
functions for a number of situations, including (1) single drug injection at the beginning, (2)
multiple drug injections over the course of treatment, and (3) continuous drug administration.
Regardless of how we administer the drug, the treatment system can be modeled as a
continuous drug delivery system. This assumption has been validated previously in vivo and in
patients across different types of cancer 86, 118.
Parameters for best model fits to experimental data (determined by Eq. 2) with the model’s
predictions from Eq. 3 are derived from:

fkill   f  t 2 ,
where ϴf is the tumor fkill coefficient (ϴf =

(Eq. 3.4)

F  λk
). From our experimental analysis, we obtain:
2VT,0

 f  A  eBSi ,

(Eq. 3.5)
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where coefficients A and B are fit to determine best values for prediction between Si absolute
mass percentage and the model output, ϴf. A and B are tumor and drug specific coefficients
specific to 4T1 breast cancer given treatment when tumors are ~500mm3 when beginning
treatment. A and B are the same for all 5 mice given the treatment described under the
experimental description used to describe the relationship between Si mass % deposited in 4T1
breast tumors and ϴf, shown in Figure 3.5.

Experiment description. Mouse experiments were performed using protocol approved by the
UNM Office of Animal Care Compliance. Six- to eight-week-old female BALB/c female mice were
given subcutaneous injections of 5 × 105 4T1 (ATCC® CRL2539™) cells into the right flank.
Tumors were grown for two weeks before treatment initiation. Average tumor volumes,
calculated from diameters measured externally with calipers, are shown in Figure 3.1. Mice
were randomly divided into three treatment groups (7 mice/group, 21 mice total): control
(PBS), free doxorubicin 1mg/kg per treatment, 1mg acetylated MSNPs (50 nm, 2.5 nm pores)
loaded with doxorubicin (equivalent 1mg/kg doxorubicin per treatment). Acetylated MSNPs
were made using the protocol described in Townson et al103, and loaded with doxorubicin using
the drug loading protocol for water soluble doxorubicin in Lin et al.135 Treatment was given
starting 2 weeks after tumor cell injections. Treatment days were as follows (t = 0 is 2 weeks
following tumor injection): 0, 2, 4, and 7. All mice were sacrificed on day 9. Tumor
measurements were taken on days: 0, 3, 7, 8, and 9. Tissues were excised and fixed in 4%
formaldehyde diluted in PBS, and then Si contents were determined using graphite furnace
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atomic absorption spectrometry as described below. Statistical analysis was conducted using
Matlab, Excel, and Graphpad Prism.

Graphite Furnace Atomic Absorption Spectrophotometry (GFAA). Analysis of Si concentration
in MSNP (mesoporous silica nanoparticle) and control (PBS) treated mice tissue was tested
using a THGA graphite furnace on a PinAAcle 900T Atomic Absorption Spectrophotometer
(Perkin Elmer, USA. Tissues tested were tumor, kidney, spleen, and liver digested using
tetramethylammonium hydroxide. Si absolute mass percentages in tissues were measured
using the standard additions method, commonly used for samples with a matrix that alters the
signal when different matrix concentrations of sample are tested. Tumor (or organ too
depending on Figure 3.2 chosen) delivery efficiency, %ID, was determined by using BALB/c
standard organ values from Tsai et al to estimate total organ Si mass deposited 136. Total Si
delivered was calculated based on Si percentage (39.36% of nanoparticle mass) added during
synthesis using the protocol in Townson el al 103. Tumor delivery efficiency was determined
using Si absolute mass percentage in the average control mice each respective organ subtracted
from that of the MSNP treated mouse and dividing it by the total administered dose over the
treatment duration. See Supplementary Information for more details on GFAA methods.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS

This chapter was adapted in part from from:
Brocato, T.*; Dogra, P.*; Koay, E. J.; Day, A.; Chuang, Y.; Wang, Z.; Cristini, V. Understanding
Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports,
2014. 6(2): p. 110-120. (*Authors contributed equally to this work)
And in part from:
Brocato, T.; Coker, E. N.; Durfee, P. N.; Lin, Y. S.; Townson, J.; Wyckoff, E. F.; Cristini V.; Wang, Z.
Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy
using Mathematical Modeling. Submitted to Nanomedicine: Nanotechnology, Biology and
Medicine.
And in part from:
Brocato, T.*; Glaberman-Brown, U.*; Wang, Z.*; Selwyn, R.; Wilson, C. M.; Wyckoff, E. F.; Lomo,
L.; Saline, J.; Pasqualini, R.; Arap, W.; Brinker, C. J.; Cristini, V. Mathematical Modeling to Predict
Response to Neoadjuvant Chemotherapy Using Breast Cancer Vasculature Characteristics.
Submitted to Science Advances. (*Authors contributed equally to this work)
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4.1 Mathematical Modeling of Chemotherapy
Chemotherapy is the mainstay of treatment for the majority of patients with breast
cancer but results in only 26% of patients with distant metastasis living 5 years past
treatment in the United States, largely because of drug resistance. The complexity of drug
resistance calls for an integrated approach of mathematical modeling and experimental
investigation to develop quantitative tools that reveal insights into drug resistance
mechanisms, predict chemotherapy efficacy, and identify novel treatment approaches. A
review has been done in Chapter 1 of recent modeling work for understanding cancer drug
resistance through the use of computer simulations of molecular signaling networks and
cancerous tissues, with a particular focus on breast cancer. These mathematical models are
developed by drawing on current advances in molecular biology, physical characterization of
tumors, and emerging drug delivery methods (e.g., nanotherapeutics). The review focused on
representative modeling works that have provided quantitative insight into chemotherapy
resistance in breast cancer and how drug resistance can be overcome or minimized to
optimize chemotherapy treatment.
4.2 Multiscale Modeling and Treatment Drug Resistance
Cancer results from multiple genetic, epigenetic, and environmental factors in a
developmental context across a number of biological scales in time and space.10 Hence,
understanding cancer drug resistance mechanisms by mathematical modeling should not be
limited to any specific biological scale, whether it is at the molecular level (gene, protein, or
signaling network) or higher, such as a tissue or organ level. By integrating data from multiple
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levels of biological complexity, modeling tumor resistance to chemotherapy drugs across
different scales can potentially be more powerful in guiding the development of new treatment
strategies. In this perspective, by taking into account important oncological characteristics such
as individual and collective cellular activities, tumor heterogeneity, and the changing
heterogeneous microenvironment, a multiscale model of drug resistance may provide a new
means of predicting the overall tumor drug resistance behavior in responding to changes that
occur on any biological scale. This research has not yet been fully explored in the field. It is also
noteworthy that the development of a successful cancer model of drug resistance is a longterm process, and that available experimental data should be used to guide the model design
and to verify and validate model results.
4.3 Diffusion Barriers Model- Neoadjuvant Treatment Prediction based on Biomarkers
Breast cancer is a model disease for the development of both targeted therapy and
prognostic and predictive biomarkers. However, predictive biomarker based treatment
selection remains an elusive goal in the management of many women with this disease. A
modeling tool was presented to predict the likelihood of response to neoadjuvant
chemotherapy using patient specific tumor vasculature biomarkers. A semi-automated analysis
was implemented to allow for increased measurement accuracy and rapid throughput in
rendering model predictions, with 3990 images, 10-208 images analyzed for each patient, in a
total of 48 patients. A previously developed histology-based model was applied to primary
resected breast cancer tumors. In effort to translate this model towards clinical practice,
prospective and a retrospective cohort of patients undergoing neoadjuvant chemotherapy
were evaluated, collecting clinically relevant data including pre- and post-treatment pathology
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specimens, and dynamic contrast-enhanced magnetic resonance imaging. Additionally response
was correlated to neoadjuvant chemotherapy with the pretreatment tumor vasculature
biomarkers and model parameters. Analysis of histology parameters, specifically radius of drug
source divided by diffusion penetration distance (L/rb), a normalization penetration distance,
and blood volume fraction (BVF), provides a separation of patients obtaining a pathologic
complete response (pCR) and those that do not, with 80% accuracy (p= 0.0269). This diffusion
barriers model has the potential to serve as predictive biomarker in the neoadjuvant setting,
thereby allowing a personalized approach to breast cancer treatment.
4.4 Future Directions
In an effort to push this research forward patient histology analysis automation has
been explored with significant findings, additionally with a non-invasive tool (MRI) to grab the
same parameters, demonstrating the importance of vasculature normality in the tumor tissue.
These parameters indicate the importance of obtaining a normal vasculature network
throughout the tumor to deliver chemotherapeutic agents. Additionally in Chapter 3, the
importance of delivering a large concentration of nanotherapeutics was demonstrated in order
to achieve exponentially greater response to treatment. The combination of mathematical
modeling to understand patient vasculature biomarkers, measured through histology and MRI,
and the importance of increasing the delivery of treatment agents to exponentially increase
treatment outcome, greatly benefits the understanding of cancer treatment outcome and
direction we need to head in. The next step would be go use this semi-automated analysis to
analyze vasculature parameters in conjunction with nanotherapeutics and their clinical
outcome. Nanoparticles as a vector for therapy delivery are shown to greatly benefit treatment
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outcomes.102 The semi-automated diffusion barriers model developed in Chapter 2 could be
further developed as a graphical user interface and be distributed for use in the clinical setting,
especially for use with pathologists and radiologists to help in the identification of positive
treatment prediction for breast cancer, in addition to expanding this model to other cancers.
The wide use of this model will help to obtain larger data sets to further determine the bounds
of the model.
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